Giovanni Leo

Giovanni Leo is partner of Lake Geneva Ventures 1, a VC fund focused on early stage start-ups, since 2020 after having held the same position at Innogest Capital from 2017. Prior to Innogest Giovanni was VP of R&D at St Jude Medical following the acquisition of Endosense in 2013, which he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias. Formerly he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. Prior to entering VC, Giovanni held leadership positions across MedTech, including at Endosense (acquired by St. Jude Medical). He is currently on the board of a number of startups including Hylomorph, EBA-med, MEdyria, Anaconda and Terapet. Giovanni previously held a software quality manager position at LeCroy Corp. as well as a CERN fellowship to carry out development activity for the control system of the Large Hadron Collider (LHC). Giovanni earned an Executive MBA in Management and Corporate Finance from the HEC of Lausanne, following a degree in management engineering from Politecnico of Milano, Italy.